Enhanced pharmacovigilance for medicinal products granted a conditional marketing authorisation is important and is already adequately provided for in Directive 2001/83/EC and Regulation (EC) No 726/2004. However, the time schedule for submitting periodic safety update reports should be adapted to accommodate the annual renewal of conditional marketing authorisations.
Recital 11, Commission Regulation (EC) No 507/2006 of 29 March 2006 on the conditional marketing aut…
In forcesince 29 Mar 2006